Navigation Links
Scientists uncover secrets of potential bioterror virus
Date:2/17/2009

GALVESTON, Texas Researchers at the University of Texas Medical Branch at Galveston have discovered a key tactic that the Rift Valley fever virus uses to disarm the defenses of infected cells.

The mosquito-borne African virus causes fever in humans, inflicting liver damage, blindness and even death on a small percentage of the people it infects. Rift Valley fever also afflicts cattle, goats and sheep, resulting in a nearly 100 percent abortion rate in these animals. Its outbreaks periodically cause economic devastation in parts of Kenya, Somalia, Sudan and Zimbabwe, and bioterrorism experts warn that its introduction to the United States would cripple the North American beef industry.

"It's really important to know how this virus causes disease, and that's what we're doing here, working to understand its pathogenicity at the molecular level," said assistant professor Tetsuro Ikegami, lead author of a paper on the discovery now appearing in PLoS Pathogens.

Ikegami and his collaborators focused on a viral protein called NSs. The protein was already known to be a major factor in making Rift Valley fever more virulent; earlier research had shown that it penetrated cell nuclei and disrupted the coding of RNA messages, including those ordering the production of the antiviral protein interferon beta.

"We didn't know what the mechanism was, but we suspected NSs had some additional function that would promote viral replication," Ikegami said. So starting with an already weakened strain of Rift Valley fever virus produced as part of a vaccine development project he created a genetically engineered form of the virus that lacked the genes for NSs.

Safety precautions make working with natural, "wild-type" Rift Valley fever virus difficult; at UTMB, investigations are restricted to a tightly secured biosafety level 4 lab, where researchers work in protective, full-body "spacesuits." By contrast, the vaccine strain of the virus that Ikegami modified, known as MP-12, can safely be handled inside a standard biosafety cabinet.

Using the NSs-free mutant virus to perform a series of cell-culture experiments, the researchers found that NSs does in fact have a second function. It attacks a protein called PKR, the beginning of a chain of biochemical reactions leading to the accumulation of a molecular complex known as phosphorylated eIF2-alpha. Phosphorylated eIF2-alpha suppresses overall protein production. Unblocked, it would prevent Rift Valley fever virus from using cellular protein synthesis machinery to make the proteins it needs to replicate itself. But since NSs prevents the phosphorylation of eIF2-alpha by taking out PKR, the virus is free to copy itself within host cells without interference.

"It's amazing that the virus evolved to use one protein to do two jobs, to use its very limited genetic information to perform these very different functions," said microbiology and immunology professor Shinji Makino, senior author of the paper. "It's really interesting, and it's also important, because these types of experiments are critical to learning how to control this virus."


'/>"/>

Contact: Jim Kelly
jpkelly@utmb.edu
409-772-8791
University of Texas Medical Branch at Galveston
Source:Eurekalert

Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Scientists Probe Sepsis Deadly Secrets
3. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
4. Scientists Develop Natural Protection for Stored Foods
5. Scientists detect presence of marburg virus in african fruit bats
6. Scientists Spot Brains Free Will Center
7. Scientists ID Likely Culprit in Popcorn Lung
8. Scientists explain how insulin secreting cells maintain their glucose sensitivity
9. Scripps Research scientists shed new light on how antibodies fight HIV
10. Scientists, physicians present latest findings in personalized cancer treatment and prevention
11. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... Schneider Insurance and ... to clients in southern Montana, is announcing a focused charity effort to gather ... outreach programs offered by Zoo Montana provide students with current knowledge on the ...
(Date:6/28/2017)... ... June 28, 2017 , ... ... servicing communities throughout the greater Cincinnati metropolitan area, is teaming up with the ... for families with children receiving treatment in nearby hospitals. , Ronald McDonald House ...
(Date:6/27/2017)... , ... June 27, 2017 , ... DrugDev ... is whether they can trust the sponsor to pay them correctly and on time. ... and CROs establish payment strategies that encourage sites to work on their studies. , ...
(Date:6/27/2017)... MA (PRWEB) , ... June 27, 2017 , ... The ... Senate bill to repeal and replace the 2010 Patient Protection and Affordable Care Act ... compared with what would be expected under current law. , More than 20 million ...
(Date:6/27/2017)... ... June 27, 2017 , ... A January 18th article on medGadget ... $6.81 billion by the year 2024 according to a new report. The article also ... made from titanium. Los Angeles area clinic Beverly Hills Periodontics & Dental Implant Center ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... ALTO, Calif. , June 9, 2017 ... device company focused on the design, manufacture, sale and ... the market on the progress of its commercial roll-out ... is now available in more than one hundred (100) ... AeroForm offers a needle-free alternative for ...
(Date:6/7/2017)... 7, 2017 Endo International plc (NASDAQ: ... the Hon. Joseph R. Goodwin , U.S. District ... West Virginia , entered a case management order ... System Products Liability Litigation (the "MDL") that includes a ... provide expert disclosures on specific causation within one hundred ...
(Date:6/3/2017)... 3, 2017  Eli Lilly and Company (NYSE: ... from the Phase 3 MONARCH 2 study showed ... inhibitor, in combination with fulvestrant, significantly improved progression-free ... in women with hormone-receptor-positive (HR+), human epidermal growth ... have relapsed or progressed after endocrine therapy (median ...
Breaking Medicine Technology: